Incyte (INCY) Expected to Post Earnings on Tuesday

Incyte (NASDAQ:INCY) is expected to post its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Incyte to post earnings of $2.15 per share and revenue of $1.4945 billion for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.38 by $0.43. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.22 billion. Incyte had a return on equity of 26.66% and a net margin of 26.71%.The company’s revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.16 earnings per share. On average, analysts expect Incyte to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Incyte Price Performance

Shares of NASDAQ INCY opened at $117.67 on Monday. The stock has a market cap of $23.51 billion, a P/E ratio of 16.62, a PEG ratio of 1.06 and a beta of 0.76. The business’s fifty day simple moving average is $106.82 and its 200-day simple moving average is $101.63. Incyte has a 12-month low of $69.69 and a 12-month high of $119.60. The company has a current ratio of 3.68, a quick ratio of 3.60 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in INCY. Atlas Capital Advisors Inc. purchased a new position in shares of Incyte during the fourth quarter worth approximately $35,000. MUFG Securities EMEA plc purchased a new stake in Incyte in the 2nd quarter valued at $32,000. CYBER HORNET ETFs LLC acquired a new stake in Incyte during the 2nd quarter worth $33,000. Triumph Capital Management acquired a new stake in Incyte during the 4th quarter worth $63,000. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Incyte during the 4th quarter worth $65,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. BMO Capital Markets upped their price target on Incyte from $94.00 to $112.00 and gave the stock a “market perform” rating in a report on Monday, July 13th. HC Wainwright reiterated a “buy” rating and issued a $140.00 price objective on shares of Incyte in a research note on Tuesday, July 21st. Morgan Stanley boosted their price objective on Incyte from $103.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Thursday. Truist Financial upped their target price on shares of Incyte from $103.00 to $105.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Finally, JPMorgan Chase & Co. raised their target price on shares of Incyte from $105.00 to $110.00 and gave the company a “neutral” rating in a report on Thursday. Eight analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $111.10.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.